Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001127602-25-001072
Filing Date
2025-01-10
Accepted
2025-01-10 17:38:04
Documents
2
Period of Report
2025-01-08

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form3.html 3  
1 PRIMARY DOCUMENT form3.xml 3 1391
2 POWER OF ATTORNEY (PUBLIC): POA doc1.txt EX-24 3891
  Complete submission text file 0001127602-25-001072.txt   6711
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Issuer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O APELLIS PHARMACEUTICALS, INC. 100 5TH AVENUE, 3RD FLOOR WALTHAM MA 02451
Business Address
Walbert Keli (Reporting) CIK: 0002051489 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38276 | Film No.: 25524115